--- title: "Precision Biosciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 10.84 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285195959.md" datetime: "2026-05-05T11:22:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285195959.md) - [en](https://longbridge.com/en/news/285195959.md) - [zh-HK](https://longbridge.com/zh-HK/news/285195959.md) --- # Precision Biosciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 10.84 M Revenue: As of FY2026 Q1, the actual value is USD 10.84 M, beating the estimate of USD 4.05 M. EPS: As of FY2026 Q1, the actual value is USD -0.75, missing the estimate of USD -0.655. EBIT: As of FY2026 Q1, the actual value is USD -9.763 M. Precision BioSciences, Inc. operates as a single operating segment focused on the discovery and development of therapies utilizing its ARCUS genome editing platform, thus all reported financial metrics apply to this single segment . #### Revenue Revenue for the three months ended March 31, 2026, was $10.8 million, a significant increase from $0.1 million for the same period in 2025, primarily due to revenue recognized under the TG License Agreement and a legacy ARCUS agriculture gene editing agreement . #### Operating Expenses Total operating expenses decreased to $19.9 million in the first quarter of 2026 from $22.1 million in the first quarter of 2025, representing a decrease of $2.2 million . **Research and Development (R&D) Expenses**: R&D expenses were $13.1 million for the three months ended March 31, 2026, down from $13.6 million for the same period in 2025, a decrease of $0.5 million . PBGENE-HBV external development costs increased to $1.8 million in 2026 from $1.6 million in 2025 . PBGENE-DMD external development costs increased to $4.0 million in 2026 from $2.4 million in 2025 . Employee-related costs for platform development and early-stage research decreased to $4.5 million in 2026 from $5.3 million in 2025 . CMOs and outsourced research and development decreased significantly to $0.1 million in 2026 from $2.1 million in 2025 . **General and Administrative (G&A) Expenses**: G&A expenses decreased to $6.8 million in 2026 from $8.6 million in 2025, a decrease of $1.8 million, primarily due to a $1.6 million decrease in employee-related costs . #### Operating Loss and Net Loss Operating loss improved to - $9.1 million in the first quarter of 2026 from - $22.1 million in the first quarter of 2025 . Net loss was - $18.4 million for the three months ended March 31, 2026, an improvement from - $20.6 million for the same period in 2025 . #### Other (Expense) Income - Gain from equity method investment was $0 in 2026 compared to $1.3 million in 2025 . - Loss on changes in other fair value adjustments was - $3.0 million in 2026, compared to $0.0 million in 2025 . - Loss on change in fair value of warrant liability was - $7.1 million in 2026, compared to - $0.8 million in 2025 . - Interest income decreased to $1.0 million in 2026 from $1.3 million in 2025 . #### Cash Flow - Net cash used in operating activities was - $11.9 million for the three months ended March 31, 2026, an improvement from - $19.1 million for the same period in 2025 . - Net cash used in investing activities was - $0.1 million in 2026, compared to - $0.3 million in 2025 . - Net cash provided by financing activities was $0.7 million in 2026, a decrease from $10.7 million in 2025 . #### Liquidity and Capital Resources As of March 31, 2026, Precision BioSciences, Inc. had cash and cash equivalents of $99.4 million and restricted cash of $26.5 million . The company had an accumulated deficit of - $546.6 million as of March 31, 2026 . #### Outlook and Strategic Updates Precision BioSciences, Inc. expects its existing cash and cash equivalents, along with its ATM facility, to be sufficient to fund operating expenses and capital expenditure requirements through 2028 . This funding is anticipated to support PBGENE-HBV and PBGENE-DMD data milestones through 2028, with further clinical data from the PBGENE-HBV program expected at medical conferences in 2026 . Additionally, iECURE is set to present clinical data from the OTC-HOPE trial in May 2026, and preliminary Phase 1 azer-cel data in progressive multiple sclerosis is expected in the second half of 2026 . #### Operational Metrics and Program Updates - **PBGENE-HBV**: The ELIMINATE-B clinical trial has treated 16 patients across five cohorts, and CTA approval was received to expand into France and Romania, with initial patient screening expected in Q2 2026 . - **PBGENE-DMD**: The FUNCTION-DMD Phase 1⁄2 clinical trial advanced with the activation of Arkansas Children’s Hospital as the first site and active patient enrollment, following FDA Fast Track designation in March 2026 . - **PBGENE-3243**: Development has been paused to prioritize other programs . - **ECUR-506 (Partnered with iECURE)**: The OTC-HOPE trial is ongoing, with preliminary clinical data expected in May 2026 . - **Azer-cel (Partnered with Imugene and TG Therapeutics)**: Imugene continues development for diffuse large B-cell lymphoma, and TG Therapeutics achieved a clinical milestone resulting in a $7.5 million payment, including $5.25 million cash and $2.25 million for common stock purchase . ### Related Stocks - [DTIL.US](https://longbridge.com/en/quote/DTIL.US.md) ## Related News & Research - [US 10-year Treasury yield expected to fall by year-end](https://longbridge.com/en/news/287011743.md) - [Acuvi shareholders approve board authorization for up to 10% share issuance](https://longbridge.com/en/news/287049993.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [Hyperscale Data declares monthly preferred dividends; record date May 31, payment June 10](https://longbridge.com/en/news/286818202.md) - [OPC Energy Q1 FY26 adjusted net profit climbs 18% to $33 million; EBITDA rises 10% to $124 million](https://longbridge.com/en/news/287057458.md)